AFT new FDA approval could be a shot in the arm

AFT new FDA approval could be a shot in the arm
Analyst sentiment is positive after FDA approval of Maxigesic IV. (Image: Hyloris Pharmaceuticals)
Ben Moore
AFT Pharmaceuticals had a bump in share price on Wednesday morning following approval of its intravenous post-operative pain relief drug by the United States Food and Drug Administration.Following the announcement of the approval of Maxigesic IV, which came in overnight, the stock lifted 16 cents per share to $3.56 at the open on the New Zealand stock exchange (NZX), up from $3.40 at yesterday's close. It has since dipped to $3.50.AFT co-founder and managing director Hartley Atkinson said they were delighted to receive the second appro...

More Markets

Iran conflict underscores dairy’s early-season risk warnings
Primary Sector

Iran conflict underscores dairy’s early-season risk warnings

The Israel-Iran war raises logistics risks for dairy but prices likely to remain steady.

Fletcher Building’s FY result won’t be pretty
Markets

Fletcher Building’s FY result won’t be pretty

No dividends will be paid until the debt target is met. 

Fletcher’s down 3.6%; NZX misses ceasefire rally
Markets Market Close

Fletcher’s down 3.6%; NZX misses ceasefire rally

 Channel Infrastructure has benefited from tensions in the Middle East, an analyst said.

Gregor Thompson 24 Jun 2025
Fletcher's restructuring, impairment costs could hit $781m
Infrastructure

Fletcher's restructuring, impairment costs could hit $781m

It expects ebit of $370m to $375m before significant items. 

Rebecca Howard 24 Jun 2025